Login to Your Account

Zilretta mo betta: Opioids voided by better choices?

By Randy Osborne
Staff Writer

Monday, October 9, 2017

Approval by the FDA of Flexion Therapeutics Inc.'s Zilretta whetted the appetite for more non-opioid drugs, the lack of which has left officials at pain-focused Centrexion Therapeutics Inc. "awestruck," Chief Medical Officer Randall Stevens told BioWorld.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription